CHEK2 and acute lymphoblastic leukemia: Finally, an in silico analysis was performed using bioinformatic tools and protein modeling to predict the functional and structural effects of these variants.<h4>Results</h4><i>CHEK2</i> GVs were identified in four patients with high-risk pre-B ALL, two carried likely pathogenic variants (2.7%) and two carried variants of uncertain significance (2.7%).